The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism
Abstract
OBJECTIVES: To construct and validate the bleeding risk prediction score, which is based on variables identified in the literature that can be easily obtained before the institution of anticoagulant therapy, in a large independent cohort of patients who were treated with anticoagulant therapy for established venous thromboembolism to allow for quantitative assessment of the risks and benefits of the therapy and to adapt the patient's management accordingly. METHODS: We constructed a bleeding risk prediction score, based on variables and their odds ratios identified in the literature, which can be easily obtained before the institution of anticoagulant therapy (score = [ 1.6 X age] + [1.3 x sex] + [2.2 X malignancy]). Subsequently, we evaluated the score in a test group of 241 patients treated with anticoagulant therapy for venous thromboembolism to determine the optimal cutoff points for the prediction of hemorrhagic complications, using receiver operating characteristic curve analysis. We then validated this score in an independent cohort of 780 patients. A score of 3 or more points, 1 to 3 points, or 0 points represented a high, intermediate, or low bleeding risk, respectively. RESULTS: The score in about one fifth of the patients in the test group was classified as predicting high risk for bleeding complications. The risk of all bleeding complications was 26% in this group and the risk of major bleeding complications was 14%. The area under the curve was 0.75 (95% confidence interval, 0.64-0.84) and 0.82 (95% confidence interval, 0.66-0.98) for all bleeding complications and major bleeding complications, respectively. When validated, there was a moderate loss of predictive power of the score, but the categorization of the patients by the score remained clinically useful; 20% of the patients were classified as high risk, and the bleeding rate was 17% for all bleeding complications and 7% for major bleeding complications compared with 4% and 1%, respectively, in those categorized as low risk. CONCLUSIONS: With the use of 3 easily obtainable, clinical variables in a prediction model, it is possible to identify a subgroup of patients at the start of anticoagulant therapy who have a high risk of developing hemorrhagic complications. Further studies should address whether additional measures to prevent bleeding decrease the bleeding incidence without compromising efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Landefeld, C. S., & Goldman, L. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90564-0 · Cited by 778
Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study
Fihn, S. D., McDonell, M., Martin, D., Henikoff, J., Vermes, D., Kent, D., White, R. H., & for the Warfarin Optimized Outpatient Follow-up Study Group* (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00005 · Cited by 671
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
van der Meer, F. J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.13.1557 · Cited by 538
Bleeding Complications in Oral Anticoagulant Therapy: An Analysis of Risk Factors
van der Meer, F. J. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410130073007 · Cited by 433
Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation
(1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440040081009 · Cited by 283
Gitter, M. J., Jaeger, T. M., Petterson, T. M., Gersh, B. J., & Silverstein, M. D. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.725 · Cited by 276
Landefeld, C. S., Cook, E. F., Flatley, M., Weisberg, M., & Goldman, L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90004-0 · Cited by 264
Nieuwenhuis, H., Albada, J., Banga, J., & Sixma, J. (1991) · Blood · doi:10.1182/blood.v78.9.2337.2337 · Cited by 226
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants
van der Meer, F. J. M., Rosendaal, F. R., Vandenbroucke, J. P., & Briët, E. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650514 · Cited by 154
Landefeld, C. S., McGuire, E. J., & Rosenblatt, M. W. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90174-c · Cited by 86
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
Wester, J. P., de Valk, H. W., Nieuwenhuis, H. K., Brouwer, C. B., van der Graaf, Y., Meuwissen, O. J., Hart, H. C., Sixma, J. J., & Banga, J. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650643 · Cited by 53
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Metadata
- Authors
- Kuijer, P. M. M., Hutten, B. A., Prins, M. H., & Büller, H. R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1999-03-08
- Volume
- 159
- Issue
- 5
- Pages
- 457
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2112681385
- Cited by
- 416
- References
- 18
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.